Stick with the maintenance plan Dr
the liquid form or the lyophilizate powder form of the composition of the present invention may be dissolved or dispersed in a solution of a biodegradable polymer such as poly(lactic-glycolic) acid copolymer, poly(hydroxybutyric acid), poly(hydroxybutyric-glycolic) acid copolymer, or the mixture of these, and then may be formulated, for example, to films, microcapsules (microspheres), or nanocapsules (nanospheres), particularly in the form of soft or hard capsules
With a benign safety profile through six-month rodent toxicology and toxicology already taken to Phase II clinical evaluation in inflammatory bowel disease (PL 14736), BPC-157 stands as one of the few research peptides with a genuinely deep, reproducible evidence base
The foremost limitation is the absence of large-scale, randomized, and well-controlled clinical trials capable of establishing definitive evidence of safety and efficacy in human populations
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D
BPC-157 may cause temporary injection site reactions in fewer than 5% of patients
